These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20077502)

  • 1. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
    De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
    Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
    Ratajska M; Antoszewska E; Piskorz A; Brozek I; Borg Å; Kusmierek H; Biernat W; Limon J
    Breast Cancer Res Treat; 2012 Jan; 131(1):89-97. PubMed ID: 21344236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
    Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
    Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
    Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
    J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
    Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Literature Review of
    Alenezi WM; Fierheller CT; Recio N; Tonin PN
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
    DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
    Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
    Ratajska M; Matusiak M; Kuzniacka A; Wasag B; Brozek I; Biernat W; Koczkowska M; Debniak J; Sniadecki M; Kozlowski P; Klonowska K; Pilyugin M; Wydra D; Laurent G; Limon J; Irminger-Finger I
    Oncol Rep; 2015 Nov; 34(5):2609-17. PubMed ID: 26329992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
    Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
    Sauer MK; Andrulis IL
    J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
    Gorringe KL; Choong DY; Visvader JE; Lindeman GJ; Campbell IG
    Breast Cancer Res Treat; 2008 Oct; 111(3):505-9. PubMed ID: 17972171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
    Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
    Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.